Soleno Therapeutics Shares Surge on Acquisition Deal with Neurocrine Biosciences

Soleno Therapeutics' stock climbed 32% on Monday after announcing a $2.9 billion acquisition by Neurocrine Biosciences. The all-cash deal, offering a 34% premium, highlights the value of Soleno's FDA-approved treatment for Prader-Willi Syndrome.

• Soleno Therapeutics' stock surged 32% on Monday following the announcement of its acquisition by Neurocrine Biosciences.
• The acquisition is valued at $2.9 billion, with Neurocrine offering $53 per share in an all-cash transaction.
• Soleno's FDA-approved treatment, Vykat XR, is the only U.S. therapy for hyperphagia associated with Prader-Willi Syndrome.
• The deal includes a 34% premium over Soleno's stock price, indicating strong interest from Neurocrine.
• The acquisition is expected to close within 90 days after receiving board approvals from both companies.
• Investors are advised to consider booking profits as Soleno's days as a standalone stock are limited.